Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1395 | Doxorubicin | Chemo | Chemotherapy | 0.01793 | -0.4166 | 0.6370 | 0.1543 | 1.1158 | 0.025315 | 0.96347 |
MDA-MB-468 | Dinaciclib | pan CDK | Cell cycle | 0.015576 | -0.4131 | 0.5681 | 0.1843 | 2.8840 | 0.018635 | 0.99641 |
MDA-MB-157 | Vorinostat | HDAC | Misc | 1.0981 | -0.4130 | 0.2980 | 0.0489 | 1.0997 | 2.487 | 0.9968 |
CAL-51 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.13353 | -0.4129 | 0.5460 | 0.1721 | 0.4106 | 1.9394 | 0.97937 |
HCC38 | Doxorubicin | Chemo | Chemotherapy | 0.0095452 | -0.4061 | 0.7803 | 0.2872 | 1.4810 | 0.01343 | 0.99228 |
HCC1806 | Ceritinib | ALK | RTK | 2.1149 | -0.4060 | 0.1766 | 0.0793 | 2.2387 | 2.8712 | 0.99364 |
HCC1419 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0091784 | -0.4046 | 0.8523 | 0.0945 | 0.5809 | 0.022714 | 0.98223 |
HCC38 | Ceritinib | ALK | RTK | 1.8283 | -0.4039 | 0.2184 | 0.0883 | 2.6153 | 2.323 | 0.99573 |
HCC1395 | Bleomycin | Radiation | Misc | 0.10419 | -0.4023 | 0.6070 | 0.1775 | 0.6889 | 0.30452 | 0.9971 |
HCC1954 | Topotecan | Topo I | Chemotherapy | 0.011912 | -0.4011 | 0.8695 | 0.3601 | 0.7510 | 0.02452 | 0.96722 |
HME1 | Doxorubicin | Chemo | Chemotherapy | 0.0047147 | -0.3985 | 0.8359 | 0.2785 | 0.9521 | 0.0078037 | 0.96003 |
HCC1954 | AZD7762 | CHK1/2 | Cell cycle | 0.12298 | -0.3978 | 0.5593 | 0.2944 | 1.4965 | 0.1737 | 0.98591 |
HCC1954 | Taxol | Chemo | Chemotherapy | 0.0024667 | -0.3961 | 0.8347 | 0.4142 | 1.6514 | 0.0034177 | 0.98666 |
PDX1258 | Buparlisib | pan PI3K | PI3K/mTOR | 1.3631 | -0.3924 | 0.2516 | 0.0862 | 1.2064 | 2.8058 | 0.99443 |
SUM149PT | Luminespib | HSP90 | Misc | 0.005116 | -0.3912 | 0.7555 | 0.3563 | 2.6742 | 0.0063272 | 0.99952 |
CAL-51 | Buparlisib | pan PI3K | PI3K/mTOR | 0.9892 | -0.3883 | 0.3283 | 0.1186 | 1.5630 | 1.5215 | 0.99245 |
SUM1315MO2 | Volasertib | PLK | Cell cycle | 0.0095 | -0.3877 | 0.6658 | 0.2263 | 2.3240 | 0.012143 | 0.99552 |
MDA-MB-231 | Vorinostat | HDAC | Misc | 1.2388 | -0.3848 | 0.2821 | 0.1116 | 1.7685 | 1.7699 | 0.99365 |
HCC1954 | Tivantinib | MET | RTK | 0.16715 | -0.3846 | 0.5511 | 0.2533 | 1.4818 | 0.24265 | 0.99675 |
HME1 | Etoposide | Topo II | Chemotherapy | 0.13797 | -0.3838 | 0.5421 | 0.1754 | 1.3297 | 0.19469 | 0.98888 |
CAL-85-1 | Luminespib | HSP90 | Misc | 0.006517 | -0.3836 | 0.7497 | 0.3002 | 4.8089 | 0.0073269 | 0.99963 |
BT-20 | Etoposide | Topo II | Chemotherapy | 0.30148 | -0.3834 | 0.4591 | 0.1362 | 1.2176 | 0.48057 | 0.99643 |
MDA-MB-468 | Neratinib | EGFR/HER2 | RTK | 0.15781 | -0.3825 | 0.3861 | 0.1513 | 0.8303 | 0.41607 | 0.99579 |
MDA-MB-436 | Cediranib | VEGFR/cKIT | RTK | 3.6098 | -0.3824 | 0.1610 | 0.0446 | 1.8229 | 6.595 | 0.98039 |
SUM159PT | Ceritinib | ALK | RTK | 1.5606 | -0.3800 | 0.2590 | 0.1427 | 2.5153 | 1.9758 | 0.99862 |